Table 2.
Clinical laboratory values for participants with chronic disease(s) in a multi-site medication therapy management (MTM) targeted intervention in Arizona (2012–16).
| Complete data N (%) | Missing or incomplete data N (%)* | Mean Value at initial consultation (SD) | Mean Change at follow up consultation (SD) | p | ||
|---|---|---|---|---|---|---|
| Diabetes (n = 48) | ||||||
| A1C (%) | 19 (39.5) | 29 (60.5) | 8.1 (1.9) | +0.2 (0.9) | 0.4572 | |
| FBG (mmol/L) | 26 (54.2) | 22 (45.8) | 148.7 (56.5) | −20.1 (59.2) | 0.0957 | |
| SBP (mmHg) | 11 (23.0) | 37 (77.0) | 133.4 (18.1) | −9.9 (18.4) | 0.1040 | |
| Hypertension (n = 128) | ||||||
| A1C (%) | 4 (3.0) | 124 (97) | 5.7 (0.6) | +0.1 (1.0) | 0.8218 | |
| FBG (mmol/L) | 6 (4.7) | 122 (95.3) | 108.7 (13.7) | 8.7 (20.6) | 0.3510 | |
| SBP(mmHg) | 71 (55.5) | 57 (44.5) | 132.0 (15.4) | −3.6 (17.7) | 0.0909 | |
| Both conditions (n = 401) | ||||||
| A1C (%) | 153 (38.2) | 248 (61.8) | 7.9 (1.7) | −0.22 (1.1) | 0.0082 | |
| FBG (mmol/L) | 254 (63.3) | 147 (36.7) | 134.0 (42.3) | −10.6 (39.4) | <0.0001 | |
| SBP (mmHg) | 196 (48.9) | 205 (51.1) | 132.6 (18.0) | −0.37 (19.4) | 0.0090 | |
A1C = hemoglobin A1C (n = 176 with complete data); FBG = fasting blood glucose (n = 286 with complete data); SBP = systolic blood pressure (n = 278 with complete data); *Mean change estimates exclude these individuals for any given biomarker